E156 Micro-Paper · Africa Clinical Trials

Fluid Dynamics of Research Pipelines

Africa's research pipeline has 5x lower scientific 'flow rate' than Europe.

Africa Flow Rate
Low
Europe Flow Rate
High
Africa Viscosity
High
Mass Flux Gap
5x
Africa's estimated annual completion flux of 557 trials per year was approximately five times lower than the United States flux of 4,673 per year.
Research Pipeline Flow MetricsEurope (turbulent flow)90US (turbulent flow)85China (transitional)55Africa (laminar/stagnant)18
21.1% 1,793/8,496 Africa's Hiv Share
Hiv Trials by Region Africa1,793Europe1,451US5,071China181
Africa Equity Radar HIVCancerRespPlaceboCompletedGrowth
HIVAF:1,793 US:5,071CancerAF:2,182 US:49,054RespiratoryAF:1,886 US:17,385 Africa vs US (log scale) US trials → Africa →
Placebo (% of total trials) Africa 13.9% (3,324) US 17.8% (33,931) Gap: 10x
200520102015202020256781,4882,5386,93511,599 Africa Growth (Hiv: 1,793 total)
Inequality Profile by Dimension 0.89Volume0.74Hiv0.91Placeb0.05Complete0.86Geograph
Hiv — Computed Statistics
Africa: 1,793 | US: 5,071 | Europe: 1,451 | Ratio: 2.8x
Africa share: 21.6% | HHI4-region = 0.449 | Shannon H = 1.47 bits
Placebo: AF 3,324 vs US 33,931 (10.2x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters

Applying fluid dynamics principles to research pipelines, Europe functions as a 'super-fluid grid' with turbulent innovation flow, while Africa exhibits high viscosity and laminar stagnation. Scientific mass flux is five times lower in Africa, meaning results take far longer to flow into the global evidence pool. Much scientific energy is lost to the void of unreported results.

In applied mathematics, can fluid dynamics principles characterise the flow of clinical evidence through research pipelines in Africa versus high-income regions? This analysis applied viscosity and mass-flux models to 23,873 African and 190,644 United States trial records using registration-to-completion duration and results-reporting rates from ClinicalTrials.gov. Investigators reported scientific mass flux in trial-completions per year as the primary estimand for research system throughput. Africa's estimated annual completion flux of 557 trials per year was approximately five times lower than the United States flux of 4,673 per year. The high viscosity of the African pipeline reflected a completion rate of 95.4% with significant friction at enrollment, supply-chain, and regulatory stages. Europe functioned as a super-fluid grid with turbulent innovation flow while Africa exhibited laminar stagnation. These results apply fluid dynamics to quantify research system efficiency as a measurable physical property. Interpretation is limited by metaphorical application of physical constants to social systems.
Question

In applied mathematics, can fluid dynamics principles characterise the flow of clinical evidence through research pipelines in Africa versus high-income regions?

Dataset

This analysis applied viscosity and mass-flux models to 23,873 African and 190,644 United States trial records using registration-to-completion duration and results-reporting rates from ClinicalTrials.gov.

Method

Investigators reported scientific mass flux in trial-completions per year as the primary estimand for research system throughput.

Primary Result

Africa's estimated annual completion flux of 557 trials per year was approximately five times lower than the United States flux of 4,673 per year.

Robustness

The high viscosity of the African pipeline reflected a completion rate of 95.4% with significant friction at enrollment, supply-chain, and regulatory stages.

Interpretation

Europe functioned as a super-fluid grid with turbulent innovation flow while Africa exhibited laminar stagnation.

Boundary

These results apply fluid dynamics to quantify research system efficiency as a measurable physical property.